American Medical Association delegates on Wednesday (June 13) asked the Justice Department and Federal Trade Commission to monitor insulin-pricing and -rebate practices of drug makers and pharmacy benefit managers, and the AMA plans to release a template for state legislators to reference as they write laws to lower insulin prices and ban so-called clawback fees and gag orders that pharmacy benefit managers impose on pharmacies. The mean price per milliliter of insulin increased nearly 200 percent from 2002 to 2013,...